US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery Market Research Reports & Industry Analysis

RSS Feeds

Drug Discovery Industry Research & Market Reports

6  7  8  9    11    13  14  15  
Ovarian Cancer Drug Pathway Analyzer 2015
1/12/2015 | published by: BioSeeker Group AB
... ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 254 drug targets that are included in this drug-pathway analyzing tool. No less than 249 of these ...  |  read more...
USD 6,746
Peptides in Oncology: Drug Pathway Analyzer 2015
1/12/2015 | published by: BioSeeker Group AB
... than 83 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 199 drug targets that are included in this drug-pathway analyzing tool. No less than ...  |  read more...
USD 6,746
Prostate Cancer Drug Pathway Analyzer 2015
1/12/2015 | published by: BioSeeker Group AB
... prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 280 drug targets that are included in this drug-pathway analyzing tool. No less than 274 of these ...  |  read more...
USD 6,746
Protein Kinase Inhibitors Drug Pathway Analyzer 2015
1/12/2015 | published by: BioSeeker Group AB
... of more than 142 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 257 drug targets that are included in this drug-pathway analyzing tool. No ...  |  read more...
USD 8,996
Renal Cancer Drug Pathway Analyzer 2015
1/12/2015 | published by: BioSeeker Group AB
... renal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 202 drug targets that are included in this drug-pathway analyzing tool. No less than 198 of these ...  |  read more...
USD 6,746
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... and the accumulated number of ceased drugs over the last years amount to another 249 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on ...  |  read more...
USD 6,746
Angiogenesis in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... amount to another 207 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 277 different targets. All included ...  |  read more...
USD 6,746
Antibodies in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... of therapeutic antibodies. There are today 354 companies plus partners developing 707 antibody drugs in 1875 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over ...  |  read more...
USD 6,746
Biologicals in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... in cancer. In addition, there are 26 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1009 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and ...  |  read more...
USD 11,246
Breast Cancer Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... below five years. There are today 400 companies plus partners developing 540 drugs targeting breast cancer in development. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
USD 6,746
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... the last years amount to another 120 drugs. Calcium Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to ...  |  read more...
USD 6,746
Cancer Drugs in the FDA Fast Lane Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... review (1992) to the most recent Breakthrough therapy (2012). This pipeline update, Cancer Drugs in the FDA Fast Lane, gives a thorough account on which cancer drugs the FDA has chosen to favor for one ...  |  read more...
USD 4,496
Cancer Stem Cells Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today 329 companies plus partners developing 448 cancer stem ...  |  read more...
USD 6,746
CAR-T Therapies in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... drug. In this regard, we have already witnessed the stellar results by Novartis and Penn University on CTL019 that left 92% of patients cancer-free in a leukemia study and performed well against lymphomas in clinical ...  |  read more...
USD 3,128
Cellular Therapy in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... years amount to another 65 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 59 different targets. ...  |  read more...
USD 4,496
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... host response. In addition, chemokines regulate plethora of biological processes of hematopoietic cells to lead cellular activation, differentiation and survival. There are today 173 companies plus partners developing 224 chemokine signaling pathway targeting drugs in ...  |  read more...
USD 6,746
Cytokine Therapy in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... amount to another 11 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 20 different targets. All ...  |  read more...
USD 4,496
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... and the accumulated number of ceased drugs over the last years amount to another 360 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each ...  |  read more...
USD 6,746
Epigenetic Therapy in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... in oncology (eg, Azacitidine, Decitabine, Vorinostat, Romidepsin, Ruxolitinib). Today a majority of drugs targets histone methylation and acetylation, also frequently dysregulated in cancer cells, in the form of inhibitors of histone acetyltransferases (HATs), histone deacetylases ...  |  read more...
USD 4,496
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation ...  |  read more...
USD 6,746
Malnutrition Global Clinical Trials Review, H2, 2014
12/15/2014 | published by: GlobalData
... relating to the clinical trials on Malnutrition. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2014
12/31/2014 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Primary Progressive Multiple Sclerosis (PPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Optic Neuritis - Pipeline Review, H2 2014
12/31/2014 | published by: Global Markets Direct
... therapeutic development for Optic Neuritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Meniere Disease - Pipeline Review, H2 2014
12/31/2014 | published by: Global Markets Direct
... therapeutic development for Meniere Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Becker Muscular Dystrophy - Pipeline Review, H2 2014
12/31/2014 | published by: Global Markets Direct
... information on the therapeutic development for Becker Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
6  7  8  9    11    13  14  15